In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
- 88 Downloads
Compliance with ethical standards
Conflict of interest
We disclose any commercial associations that might pose a potential, perceived or real conflict of interest with the content of this article. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, donations, advisory board memberships, or payments for conducting or publicizing the study.
- 2.Suton P, Skelin M, Rakusic Z, Dokuzovic S, Luksic I (2019) Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. Eur Arch Oto-Rhino-Laryngol 276:1275–1281. https://doi.org/10.1007/s00405-019-05387-8 CrossRefGoogle Scholar
- 3.Riaz N, Baschnagel A, Adkins D, Rao S, Huang J, Chen P et al (2014) Multi-institution analysis of concurrent chemoradiation therapy with cisplatin (CDDP) versus cetuximab (C225) in locally advanced squamous cell carcinoma of the head and neck (LAHNSCC): can HPV help decide which agent? Int J Radiat Oncol Biol Phys 88:472CrossRefGoogle Scholar